The preventive effect of Sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinka alcaloid induced peripheral neuropathies

The preventive effect of Sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinka alcaloid induced peripheral neuropathies - STOP

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006088

Enrollment

158

Registered

2014-05-07

Start date

2014-05-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C75 C50-C50 C15-C26 C81-C96

Interventions

Group 1: Sensorimotor training: the exercises are progressively difficult, starting bipedal on a static surface to monopedal on an instable surface. Four exercises will be performed per training sessi

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: >18years old indication for chemotherapy containing either Oxaliplatin or vinka alcaloid

Exclusion criteria

Exclusion criteria: - PNP (NCV <40; amp <5) of other derivation (such as diabetes, HIV, alcohol) - all conditions preventing the active particpation in physical activity - contraindications for vibration exercises (osteolyses, osteosyntheses, hip-TEP, a fracture of the lower extremities in the past 2 years, acute thrombosis, foot ulcers, fresh wounds and scar tissue) - planed operation - unwillingness to sign the informed consent and data protection - uncontrolled cerebral seizures - CNS metastases - physical or psychological condition that does not allow the participation in a study or a legal signature for the informed consent statement, according to the principal investigator

Design outcomes

Primary

Measure	Time frame
Onset and time-point of chemotherapy-induced peripheral neuropathy (Nerve conduction velocity (<40) and amplitude (<5) via neuroeletrography, Achilles- and patellar reflexes with a reflex hammer, peripheral deep sensitivity with a tuning fork, proprioception- manually) Baseline assessment will be performed prior to therapy (T0), once neuropathy related symptoms are reported (T1) (which will also be checked every 6 weeks via a short neurological assessment -solely excluding the neuroelectrography) and after completion of therapy - after 2-3months (T2). In case therapy continues for more than 3 months, T2 will be performed as an intermediate measuring point and a further will be necessary after completion of therapy (T3).	—

Measure

Time frame

Onset and time-point of chemotherapy-induced peripheral neuropathy (Nerve conduction velocity (<40) and amplitude (<5) via neuroeletrography, Achilles- and patellar reflexes with a reflex hammer, peripheral deep sensitivity with a tuning fork, proprioception- manually) Baseline assessment will be performed prior to therapy (T0), once neuropathy related symptoms are reported (T1) (which will also be checked every 6 weeks via a short neurological assessment -solely excluding the neuroelectrography) and after completion of therapy - after 2-3months (T2). In case therapy continues for more than 3 months, T2 will be performed as an intermediate measuring point and a further will be necessary after completion of therapy (T3).

—

Secondary

Measure	Time frame
subjective assessment of neuropathy related symptoms (FACT-gog-ntx) Quality of life (EORTC-QLQ-C-30) Neuropathy related pain (PAIN-DETECT) level of activity (GPAQ) Baseline assessment will be performed prior to therapy (T0), once neuropathy related symptoms are reported or identified (T1) and after completion of therapy - after 2-3months (T2). In case therapy continues for more than 3 months, T2 will be performed as an intermediate measuring point and a further will be necessary after completion of therapy (T3).	—

Measure

Time frame

subjective assessment of neuropathy related symptoms (FACT-gog-ntx) Quality of life (EORTC-QLQ-C-30) Neuropathy related pain (PAIN-DETECT) level of activity (GPAQ) Baseline assessment will be performed prior to therapy (T0), once neuropathy related symptoms are reported or identified (T1) and after completion of therapy - after 2-3months (T2). In case therapy continues for more than 3 months, T2 will be performed as an intermediate measuring point and a further will be necessary after completion of therapy (T3).

—

Countries

Germany

Contacts

Public ContactFiona Streckmann

Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abt. II

f.streckmann@dshs-koeln.de0221 4982 4821

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 7, 2026